Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  bleomycin sulfate
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 35 for your search:
Start Over
Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 to 75
Sponsor: Other
Protocol IDs: CGC05MK1002, NCT00188149
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 16
Sponsor: Other
Protocol IDs: CDR0000416124, FRE-FNCLCC-GETUG-13/0206, EU-20502, NCT00104676
Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma
Phase: Phase III
Type: Diagnostic, Treatment
Status: Active
Age: 17 and under
Sponsor: Other
Protocol IDs: CDR0000531687, EURONET-PHL-C1, EU-20703, EUDRACT-2006-000995-33, CCLG-HD-2007-10, NCT00433459
HD16 for Early Stage Hodgkin Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: HD16, NCT00736320
Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 16 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: ASI-HDIII 0109, NCT00816959
Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: CDR0000633503, GOELAMS-LH2007, GOELAMS-ID-RCB#2007-A01079-44, INCA-RECF0754, AMGEN-GOELAMS-LH2007, NCT00920153
HD17 for Intermediate Stage Hodgkin Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: HD17, NCT01356680
Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: ACTG A5263, 1U01AI068636, U01CA121947, NCT01435018
GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma
Phase: Phase III
Type: Diagnostic, Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: GAINED, NCT01659099
Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C25003, 2011-005450-60, U1111-1161-4937, 12/LO/1950, JapicCTI-142491, NCT01712490
A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: CSWOG0002, NCT01788137
Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Supportive care, Treatment
Status: Active
Age: 18 and younger
Sponsor: NCI
Protocol IDs: NCI-2014-01223, AHOD1331, NCT02166463
Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: 2014/2012, 2014-004075-23, NCT02341989
Treatment of Primary Liver Tumors With Electrochemotherapy (ECT)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 21K/02/14, NCT02291133
Vinblastine, Cyclophosphamide, Procarbazine, Prednisolone, Etoposide, Mitoxantrone, and Bleomycin in Treating Older Patients With Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: CDR0000354225, UON-SHIELD, EU-20346, NCT00079105
Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL)
Phase: Phase II
Type: Diagnostic, Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: GITIL - HD0607, NCT00795613
Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: ASI-HDII 1108, NCT00797472
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: HOD08, NCI-2009-01138, NCT00846742
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: GOG-0264, NCI-2011-02000, CDR0000662814, U10CA027469, NCT01042522
Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: 18 to 60
Sponsor: NCI, Other
Protocol IDs: CALGB-50801, CDR0000669076, NCI-2011-02034, NCT01118026
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: 18 to 60
Sponsor: NCI, Other
Protocol IDs: CDR0000672913, CALGB-50604, NCT01132807
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000702859, ECOG-E2410, E2410, NCT01390584
Prospective Study on HIV-related Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: HIV-HL 2004, NCT01468740
A Study to Evaluate the Safety and Efficacy of PC-A11 in Patients With Recurrent Head and Neck Squamous Cell Carcinoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCIA202/10, 2011-003751-19, NCT01606566
Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: H-30993 TXCH-HD-12A, TXCH-HD-12A, NCT01858922
Start Over